Sinorda Pharmaceutical and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

SHANGHAI, Jan. 29, 2026–Sinorda Pharmaceutical, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune diseases, today announced it has entered into a strategic collaboration agreement with WuXi Biologics (2269.HK). The partnership is specifically designed to accelerate the preclinical pharmacology studies and clinical manufacturing of SND006, Sinorda’s independently developed, novel bispecific antibody.

Dr. Zhisheng Chen, Chief Executive Officer of WuXi Biologics (right), and Dr. Pingsheng Hu, Chairman and General Manager of Synnovate Biopharma, signed a strategic cooperation agreement (left).

Pioneering a New Treatment for Autoimmune Diseases
SND006 is a potential best-in-class bispecific antibody discovered and developed by Sinorda Pharmaceutical. Sinorda holds full worldwide rights to this molecule, which is currently being developed as a breakthrough treatment for Inflammatory Bowel Disease (IBD) and other severe autoimmune conditions.

Following the successful completion of in vitro functional validation, Sinorda is now entering the next phase of its development strategy. By leveraging the manufacturing expertise of WuXi Biologics, Sinorda aims to streamline its Investigational New Drug (IND) application process, with plans to submit filings to the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA) within 2026.

Strengthening the Pipeline through Strategic Collaboration

Dr. Pingsheng Hu, Chairman and General Manager of Sinorda Pharmaceutical, stated:

"The development of SND006 is a testament to Sinorda's commitment to delivering breakthroughs in the treatment of gastrointestinal and autoimmune diseases. By collaborating with a global CRDMO leader like WuXi Biologics, we are strategically enhancing our ability to bring this innovative biologic from our lab to patients more rapidly. This partnership not only accelerates the IND filings for SND006 but also sets a strong foundation for the future growth of our entire pipeline as we address critical unmet medical needs worldwide."

Dr. Chris Chen, CEO of WuXi Biologics, commented:

"Over the past decade, we have accumulated experience across hundreds of projects in bispecific and multispecific antibodies, which have become one of our fastest‑growing areas. We are pleased to accelerate the development and manufacturing of Sinorda Pharmaceutical’s innovative bispecific antibody SND006 through our integrated technology platforms and comprehensive capabilities. Looking ahead, we will continue accelerating and transforming biologics discovery, development and manufacturing to empower global partners and make innovative biologics more accessible and affordable for patients worldwide."

Future Growth and Vision

This collaboration marks the beginning of a broader partnership. Moving forward, Sinorda Pharmaceutical plans to further expand its cooperation with WuXi Biologics across its potential pipeline. The roadmap includes multiple integrated projects ranging from molecule discovery and validation to full-scale clinical manufacturing, reinforcing Sinorda’s position as a rising leader in the innovative biologics sector.

About Sinorda Pharmaceutical

Sinorda Pharmaceutical is a leading-edge biopharmaceutical company focused on the discovery and clinical development of innovative therapies for autoimmune and gastrointestinal diseases. With a robust R&D engine and a focus on high-value targets, Sinorda is dedicated to bringing safe, effective, and transformative treatments to patients globally.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.